Kane Biotech Inc (KNE) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.912x

Based on the latest financial reports, Kane Biotech Inc (KNE) has a cash flow conversion efficiency ratio of 0.912x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-680.61K ≈ $-492.35K USD) by net assets (CA$-746.54K ≈ $-540.04K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KNE cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Kane Biotech Inc - Cash Flow Conversion Efficiency Trend (2003–2025)

This chart illustrates how Kane Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Kane Biotech Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kane Biotech Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Euroespes S.A. MC:EEP	0.003x
iDimension Consolidated Bhd KLSE:0174	0.001x
SIMFABRIC SA ZY-10 F:853	0.139x
Cooper Metals Ltd AU:CPM	-0.020x
Indaptus Therapeutics Inc NASDAQ:INDP	-1.012x
RENFORTH RESS. INC. NEW F:9RR	0.400x
International Lithium Corp V:ILC	-0.028x
Inix Technologies Holdings Bhd KLSE:0094	0.015x

Annual Cash Flow Conversion Efficiency for Kane Biotech Inc (2003–2025)

The table below shows the annual cash flow conversion efficiency of Kane Biotech Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Kane Biotech Inc (KNE) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CA$-746.54K ≈ $-540.04K	CA$-3.26 Million ≈ $-2.35 Million	4.361x	+72.80%
2024-12-31	CA$-1.63 Million ≈ $-1.18 Million	CA$-4.11 Million ≈ $-2.97 Million	2.523x	+919.19%
2023-12-31	CA$-8.41 Million ≈ $-6.08 Million	CA$-2.08 Million ≈ $-1.51 Million	0.248x	-66.34%
2022-12-31	CA$-4.14 Million ≈ $-2.99 Million	CA$-3.04 Million ≈ $-2.20 Million	0.736x	-49.65%
2021-12-31	CA$-1.57 Million ≈ $-1.13 Million	CA$-2.29 Million ≈ $-1.66 Million	1.461x	+139.86%
2020-12-31	CA$1.07 Million ≈ $777.45K	CA$-3.94 Million ≈ $-2.85 Million	-3.665x	-221.02%
2019-12-31	CA$836.81K ≈ $605.33K	CA$-955.37K ≈ $-691.10K	-1.142x	-139.40%
2018-12-31	CA$-984.84K ≈ $-712.42K	CA$-2.85 Million ≈ $-2.06 Million	2.898x	+488.15%
2017-12-31	CA$2.74 Million ≈ $1.98 Million	CA$-2.04 Million ≈ $-1.48 Million	-0.747x	+57.43%
2016-12-31	CA$1.35 Million ≈ $974.76K	CA$-2.36 Million ≈ $-1.71 Million	-1.754x	+39.34%
2015-12-31	CA$480.25K ≈ $347.40K	CA$-1.39 Million ≈ $-1.00 Million	-2.891x	-265.11%
2014-12-31	CA$1.32 Million ≈ $958.43K	CA$-1.05 Million ≈ $-758.95K	-0.792x	+12.89%
2013-12-31	CA$1.28 Million ≈ $928.25K	CA$-1.17 Million ≈ $-843.79K	-0.909x	-84.75%
2012-12-31	CA$2.35 Million ≈ $1.70 Million	CA$-1.16 Million ≈ $-835.72K	-0.492x	-24.43%
2011-12-31	CA$2.38 Million ≈ $1.72 Million	CA$-940.30K ≈ $-680.20K	-0.395x	+41.91%
2010-12-31	CA$1.16 Million ≈ $841.74K	CA$-792.06K ≈ $-572.96K	-0.681x	-60.08%
2009-12-31	CA$1.80 Million ≈ $1.30 Million	CA$-764.26K ≈ $-552.85K	-0.425x	+40.87%
2008-12-31	CA$1.49 Million ≈ $1.08 Million	CA$-1.07 Million ≈ $-776.48K	-0.719x	-2.74%
2007-12-31	CA$1.14 Million ≈ $825.19K	CA$-798.38K ≈ $-577.53K	-0.700x	-18.27%
2006-12-31	CA$1.42 Million ≈ $1.03 Million	CA$-843.13K ≈ $-609.91K	-0.592x	+25.57%
2005-12-31	CA$1.02 Million ≈ $735.99K	CA$-808.87K ≈ $-585.12K	-0.795x	+32.63%
2004-12-31	CA$426.65K ≈ $308.63K	CA$-503.50K ≈ $-364.22K	-1.180x	-178.44%
2003-12-31	CA$955.27K ≈ $691.03K	CA$-404.87K ≈ $-292.88K	-0.424x	--

About Kane Biotech Inc

V:KNE Canada Biotechnology

Market Cap

$3.95 Million

CA$5.46 Million CAD

Market Cap Rank

#28994 Global

#1349 in Canada

Share Price

CA$0.03

Change (1 day)

+0.00%

52-Week Range

CA$0.03 - CA$0.06

All Time High

CA$0.40